This decision had a major impact

[israt9623525]

The public nature of the project and its emphasis on making genetic data readily available contrasted with the commercial interests that sought to patent genes. Society of Molecular Pathology v. Myriad Genetics (2013) In another landmark US Supreme Court case, the court ruled that naturally occurring DNA sequences cannot be patented, although cDNA (complementary DNA), which is created synthetically, can. on the biotechnology industry, especially on companies like Myriad Genetics that held patents on the BRCA1 and BRCA2 genes. 2. Types of Genetic Material Patents Isolated Gene Sequences Patents on isolated gene sequences involve claims on specific DNA sequences that are extracted from their natural environment and have been identified for their utility.


For example, Myriad Genetics' patents on pitcairn island business email list BRCA1 and BRCA2 gene sequences were significant because they were related to tests that predicted the risk of breast and ovarian cancer. Synthetic Genes Synthetic genes, or cDNA, are created in the laboratory using reverse transcription of mRNA. These synthetic versions of naturally occurring genes can be patented. The ability to patent cDNA was confirmed in the Myriad Genetics case, which distinguishes it from naturally occurring DNA. Gene Therapies and CRISPR Technology Innovations in gene therapies and gene editing technologies, such as CRISPR-Cas9, have introduced new frontiers in gene patenting.